The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
126735111 12673511 1 I 201603 20160610 20160822 20160822 EXP US-BAYER-2016-115872 BAYER 79.00 YR E M Y 0.00000 20160822 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
126735111 12673511 1 PS NEXAVAR SORAFENIB 1 Oral 400 MG, BID 21923 400 MG FILM-COATED TABLET BID
126735111 12673511 2 SS NEXAVAR SORAFENIB 1 Oral 200 MG, BID 21923 200 MG FILM-COATED TABLET BID
126735111 12673511 3 C OXYCODONE OXYCODONE 1 0
126735111 12673511 4 C SENOKOT SENNOSIDES 1 0
126735111 12673511 5 C PRILOSEC OMEPRAZOLE MAGNESIUM 1 0
126735111 12673511 6 C SPIRONOLACTONE. SPIRONOLACTONE 1 UNK UNK, BID 0 BID
126735111 12673511 7 C NAPROXEN. NAPROXEN 1 500 MG, BID 0 500 MG BID
126735111 12673511 8 C NAPROXEN. NAPROXEN 1 0
126735111 12673511 9 C LACTULOSE. LACTULOSE 1 15 MG, BID 0 15 MG BID

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
126735111 12673511 1 Hepatocellular carcinoma
126735111 12673511 2 Hepatocellular carcinoma
126735111 12673511 3 Pain
126735111 12673511 4 Constipation
126735111 12673511 5 Gastrooesophageal reflux disease
126735111 12673511 6 Oedema
126735111 12673511 7 Abdominal pain upper
126735111 12673511 8 Night sweats
126735111 12673511 9 Constipation

Outcome of event

Event ID CASEID OUTC COD
126735111 12673511 DE
126735111 12673511 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
126735111 12673511 Abdominal distension
126735111 12673511 Abdominal pain
126735111 12673511 Abdominal pain upper
126735111 12673511 Abdominal tenderness
126735111 12673511 Back pain
126735111 12673511 Blood pressure decreased
126735111 12673511 Breath odour
126735111 12673511 Chest X-ray abnormal
126735111 12673511 Death
126735111 12673511 Dry mouth
126735111 12673511 Dyspnoea
126735111 12673511 General physical health deterioration
126735111 12673511 Heart rate increased
126735111 12673511 Hepatic cancer
126735111 12673511 Hepatic encephalopathy
126735111 12673511 Infrequent bowel movements
126735111 12673511 Insomnia
126735111 12673511 Nausea
126735111 12673511 Neoplasm progression
126735111 12673511 Oxygen saturation decreased
126735111 12673511 Penile ulceration
126735111 12673511 Pleural effusion
126735111 12673511 Pulmonary physical examination abnormal
126735111 12673511 Respiratory failure
126735111 12673511 Stomatitis
126735111 12673511 Urine output decreased
126735111 12673511 Vomiting
126735111 12673511 Weight decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
126735111 12673511 1 201603 2016 0
126735111 12673511 2 2016 2016 0